Overall, by integrated analysis of TCGA and GEO datasets, our results provide deep understandings of how the KRAS, TP53, CDKN2A and SMAD4 genetic alterations and their related genes influence the clinical overall survival of pancreatic cancer patients. This evidence concerns the gene TP53 and familial pancreatic carcinoma.